A phase 3 trial confirms “the potent anti-leukemic effect” of consolidation with allogeneic transplant in older patients with acute myeloid leukemia, according to researchers.
The medicines and health conditions are: venetoclax (brand name Venclexta) in combination with azacitidine or cytarabine for a type of blood cancer called acute myeloid leukaemia azacitidine to be ...